Push for greater R&D and innovation in Africa


Published on

Presentation by the African Network for Drugs & Diagnostics Innovation made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Push for greater R&D and innovation in Africa

  1. 1. Push for greater R&D and innovation in Africa Solomon Nwaka. ANDI Director a.i. EAHIC London, March 26-27, 2013
  2. 2. Presentation to address following question! • What is the potential & capacity for health product R&D and innovation in Africa? • How can we stimulate collaboration between local pharma industry, academia and public sector? 2
  3. 3. Outline of presentation • Landscape for product R&D and access for diseases that disproportionately affect developing countries, esp Africa • Health product/pharmaceutical R&D in Africa • ANDI and other initiatives • Summary & conclusions 3
  4. 4. Global landscape for product R&D and innovation • PDPs, PPPs & dedicated industry activities • Academia – screens, genomics, MedChem, ADMET • Network and consortia based mechanism • Government or intergovernmental effort • Open source & open innovation approaches • Product access and procurement initiatives • Funding from government & philanthropy ANDI is presently the only product R&D coordination mechanism operating on a pan African basis 4
  5. 5. 'Innovation gap' remain: e.g. drugs Nwaka et al. 2009 5
  6. 6. A global innovation framework for diseases that 'disproportionately affect developing countries' • Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPoA) ▪ Agreed by ALL countries in World Health Assembly Resolution 61.21 ▪ Emphasise country level & regional innovation in developing countries ▪ Financing and coordination mechanisms being discussed ▪ www.who.int/phi • Designed to promote: ▪ innovation ▪ build capacity ▪ improve access to innovation ▪ mobilize resources 6
  7. 7. Research and pharmaceuticals in Africa • Africa home to medicines – traditional & herbal remedies • Growing emphasis on pharmaceutical R&D, manufacture and capacity building ▪ AU Pharmaceutical Manufacturing Plan ▪ AMCOST Cairo Declaration of 2006, 'promote R&D and develop innovation strategies for wealth creation and economic development' ▪ Algiers declaration on research for health 2008 ▪ Globally competitive R&D institutions and SMEs exist • But existing capacity not coordinated or leveraged to solve African health challenges ▪ limited intra-African collaboration, limited capacity utilization • Enhanced intra-African collaboration will boost North South/South South partnerships 7
  8. 8. Increasing African R&D support but a more holistic approach needed • Multilateral Initiative for Malaria ▪ Provided small grants (MIM/TDR) but grant now discontinued ▪ Secretariat transferred to AMANET, Tanzania in 2005, now hosted Univ. Yaoundé • EDCTP ▪ Strong African engagement in management and governance (African office) • Many agencies now fund direct to African institutions ▪ NIH, EU, Wellcome Trust, Gates Foundation, DFID/MRC……. • Increasing number of African countries establishing research councils • AU / NEPAD ▪ Direct engagement in fostering research and capacity building ▪ Local product and regulatory activities
  9. 9. ANDI responds to the need for coordination 9
  10. 10. Evolution and background of ANDI 10
  11. 11. ANDI establishment informed by landscape analysis 5 50 66 176 Country visits ▪ ▪ ▪ ▪ ▪ Interviews outside of Africa ▪ Group interviews ▪ 1-on-1 interviews ▪ Phone interviews Data sources ▪ ▪ ▪ ▪ Interviews in Africa ▪ 1-on-1 interviews ▪ Focus groups ▪ Plenary sessions South Africa Nigeria Egypt Kenya Burkina Faso > 30,000 papers analyzed > 1,500 clinical trials analyzed > 160 African patents analyzed > 120 pharmaceutical companies surveyed Note: sources consulted included databases, institutional web pages and reports (foundations, PPPs, pharma companies) SOURCE: Country visits, interviews 11
  12. 12. Lack of collaboration in Africa…HIV/AIDS research Only 5% of articles are in collaboration between two or more African countries SOURCE: Thomson Web of Science, UCINET 12
  13. 13. Good news - competency research centers exist • Cities with 30 or more articles published in the 2004 - 2008 period • Total of 90 cities in 27 countries • 16,647 biomedical articles led by African authors included in analysis Note: Only top 40 cities by research output labeled SOURCE: Thomson Web of Science 13
  14. 14. Potential downstream partners for product manufacture & commercialization exist Pharmaceutical manufacturing Tunisia Morocco Algeria Libya Western Sahara Egypt Mauritania Mali Cape Verde Sudan Niger Senegal Eritrea Chad Gambia Guinea Bissau Burkina Guinea Sierra Leone Liberia Djibouti Central African Republic Nigeria Ethiopia Ivory Coast Uganda Cameroon Ghana Benin Equatorial Togo ▪ Total of 129 companies identified ▪ Most companies locate to Egypt, SA, Nigeria, Morocco and Algeria ▪ Estimated average sales for identified companies of ~USD 90 million/year Guinea Somalia Zaire Gabon Congo Kenya Rwanda Burundi Tanzania Malawi Angola Mozambique Zambia Namibia Zimbabwe Botswana South Africa Madagascar Swaziland Lesotho SOURCE: OneSource, company websites, press searches 14
  15. 15. ANDI mission & vision Mission Statement "To promote and sustain African-led health product innovation to address African public health needs through the assembly of research networks, and building of capacity to support human and economic development" Vision "Creating a sustainable platform for R&D innovation in Africa to address Africa’s own health needs" 15
  16. 16. Governance • Hosting Agency ▪ Being transitioned out of UNECA • Board ▪ Co-Chaired – Minister of Health, Kenya – Minister of S &T, S Africa ▪ 12 members with >75% from Africa ▪ WHO, AfDB & host agency • Secretariat ▪ Operates through regional hubs 16
  17. 17. Viable projects exist in Africa- call for projects implemented Capacity for innovation exist in Africa but need to be coordinated for optimal result Covers product R&D, manufacturing, commercialization 17
  18. 18. CoEs implemented through a rigorous process Capacity for innovation exist in Africa but need to be coordinated for optimal result Covers product R&D, manufacturing, commercialization 18
  19. 19. Approved CoEs, incl manufacturers National Institute for Pharmaceutical Research and Development University of Ibadan Institut Pasteur de Tunis Theodor Bilharz Reseach Institute Vacsera (2) Vacsera Manufacturing University of Lagos National Center for Research Joint Clinical Research Center University of Bamako Kumasi Center for Collaborative Research LaGray Chemical Co. Ltd Noguchi Memorial Institute for Medical Research University of Buea Institut de recherches médicales et d'études des plantes médicinales African Institute of Biomedical Science and Technology Makerere University KEMRI Production Unit Institute of Primate Research Kenya Medical Research Institute Kenya Agricultural Research Institute Kilimanjaro School of Pharmacy University of Zambia University of Mauritius Stellenbosch University (2) The Biovac Insttute University of Cape Town (3) IThemba Labs South African Medical Research Council Botswana Vaccine Institute Council for Scientific and Industrial Research IThemba Pharma University of Witwatersrand (2) 19
  20. 20. CoE mapped around value chain - DRUGS Product Value Chain Research & Development Clinical Studies to Registration Manufacturing & Market access Impact 20
  21. 21. Analysis of CoE reveal most frequent donors of health innovation in Africa – Nwaka et al. BMC 2012 21
  22. 22. Other challenges for R&D & manufacture in Africa $$$$$$$$$$$$$$$ Regulation Infrastructure 22
  23. 23. Many partners needed • Political leadership and ownership ▪ AU, NEPAD, AfDB, governmental-led governance • Technical leadership and ownership ▪ Research institutions, Pharma, National agencies ▪ Diaspora ▪ Build on ANDI business plan • Financial leadership ▪ Governments, development partners, AfDB
  24. 24. Questions addressed! • The potential & capacity for health product R&D and innovation exist in Africa • We need to leverage existing capacity to build more capacity (concept of capacity utilization) • Strong political will and support critical • Collaboration between local pharma industry, academia and public sector has great potential • Work on ANDI CoEs show that this can happen • Encourage research based companies that can collaborate and take on leads from academia • Incentives schemes to encourage PPPs and tech transfer 24
  25. 25. >500 people at ANDI Stakeholders Meetings 25
  26. 26. Acknowledgment • WHO incl. TDR, PHI, AFRO, EMRO • Economic Commission for Africa (UNECA) • African Development Bank (AfDB) • European Commission (EC), also for financial support • African Union (AU) • African institutions & scientists • Nigeria for funding support • McKinsey & Co • ANDI STAC and former task force 26